TRILIPIX

This brand name is authorized in Ecuador, Singapore, United States

Active ingredients

The drug TRILIPIX contains one active pharmaceutical ingredient (API):

1 Fenofibrate UNII BGF9MN2HU1 - FENOFIBRIC ACID

Fenofibrate is a fibric acid derivative whose lipid modifying effects reported in humans are mediated via activation of Peroxisome Proliferator Activated Receptor type α (PPARα). Through activation of PPARα, fenofibrate increases lipolysis and elimination of atherogenic triglyceride rich particles from plasma by activating lipoprotein lipase and reducing production of Apoprotein C-III. Read about Fenofibrate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TRILIPIX Delayed release capsule	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
C10AB11		C Cardiovascular system → C10 Lipid modifying agents → C10A Lipid modifying agents, plain → C10AB Fibrates
Discover more medicines within C10AB11

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 844-MEE-0315
Country: US	FDA, National Drug Code	Identifier(s): 0074-3161, 0074-3162, 0074-9189, 0074-9642